Literature DB >> 8490101

Cell surface glycoproteins expressed on activated human T cells induce production of interleukin-1 beta by monocytic cells: a possible role of CD69.

P Isler1, E Vey, J H Zhang, J M Dayer.   

Abstract

In many immunoinflammatory diseases, macrophages, by producing interleukin-1 (IL-1) and tumor necrosis factor alpha (TNF alpha), stimulate protease secretion in fibroblasts, thus contributing to tissue destruction. Monocyte/macrophage activation is prompted by soluble factors released by activated T cells as well as by cell-cell contact. Indeed, previous studies have shown that monocytes exposed to paraformaldehyde (PFA)-fixed, activated T cells produced high amounts of IL-1 beta. In this report, we used the T cell line HUT-78 to further characterize the T cell factor(s) responsible for monocyte activation by cell-cell contact. After subcellular fractionation, most of the activity was found in the cellular membrane fraction of PHA/PMA-stimulated HUT-78 cells, and proved to be due to glycoproteins, following trypsin digestion and tunicamycin treatment. HUT-78 cells acquired the capacity to stimulate monocytic cells after as little as 1h of stimulation. De novo protein synthesis was required for the expression of the IL-1 beta inducing factor, as shown by cycloheximide treatment. When membrane proteins of PHA/PMA-stimulated HUT-78 cells were separated on SDS-polyacrylamide gel, a peak of stimulatory activity was observed at Mr--25-35 x 10(3). By using specific cytokine inhibitors or blocking mAbs, we ascertained that cell-associated cytokines (IL-1, IL-2, IFN gamma and GM-CSF) were not involved in monocyte activation by cell contact. Anti-CD2 and -CD11a (LFA-1) mAbs partially blocked IL-1 beta production by -25% and -35%, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8490101

Source DB:  PubMed          Journal:  Eur Cytokine Netw        ISSN: 1148-5493            Impact factor:   2.737


  31 in total

1.  Activation of p38 mitogen-activated protein kinase is critical step for acquisition of effector function in cytokine-activated T cells, but acts as a negative regulator in T cells activated through the T-cell receptor.

Authors:  Ching Li; Paul Beavis; Andrew C Palfreeman; Parisa Amjadi; Alan Kennedy; Fionula M Brennan
Journal:  Immunology       Date:  2010-09-28       Impact factor: 7.397

Review 2.  Aortic aneurysms: an immune disease with a strong genetic component.

Authors:  Helena Kuivaniemi; Chris D Platsoucas; M David Tilson
Journal:  Circulation       Date:  2008-01-15       Impact factor: 29.690

Review 3.  Cytokine therapy in rheumatoid arthritis.

Authors:  J Hermann; M Walmsley; F M Brennan
Journal:  Springer Semin Immunopathol       Date:  1998

Review 4.  Anti-CD4 monoclonal antibodies in rheumatoid arthritis.

Authors:  E H Choy; G H Kingsley; G S Panayi
Journal:  Springer Semin Immunopathol       Date:  1998

Review 5.  Antigen-presenting cells in rheumatoid arthritis.

Authors:  R Thomas
Journal:  Springer Semin Immunopathol       Date:  1998

6.  Biological insights from clinical trials with anti-TNF therapy.

Authors:  M Feldmann; P Charles; P Taylor; R N Maini
Journal:  Springer Semin Immunopathol       Date:  1998

7.  Enhancement of Mycobacterium tuberculosis-induced tumor necrosis factor alpha production from primary human monocytes by an activated T-cell membrane-mediated mechanism.

Authors:  J Warwick-Davies; A J Watson; G E Griffin; S Krishna; R J Shattock
Journal:  Infect Immun       Date:  2001-11       Impact factor: 3.441

Review 8.  Leflunomide: mode of action in the treatment of rheumatoid arthritis.

Authors:  F C Breedveld; J M Dayer
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

Review 9.  Role of pro-inflammatory cytokines in rheumatoid arthritis.

Authors:  F M Brennan; R N Maini; M Feldmann
Journal:  Springer Semin Immunopathol       Date:  1998

10.  Inhibition of tumour necrosis factor and IL-17 production by leflunomide involves the JAK/STAT pathway.

Authors:  I González-Alvaro; A M Ortiz; C Domínguez-Jiménez; A Aragón-Bodi; B Díaz Sánchez; F Sánchez-Madrid
Journal:  Ann Rheum Dis       Date:  2008-10-28       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.